1. What are the big companies in China?
1. According to statistics, 327 varieties and 949 batches of new western medicines were developed in China last year. Last year, Lu Kang, Shanghai Xinya * * and other 18 state-owned enterprises developed 47 varieties and 76 batches of western medicines, while 20 joint ventures such as Shanghai Johnson & Johnson and Zhuhai Bangyuan also developed 34 varieties and 52 batches of western medicines. The research and development of this kind of new drugs is obviously stronger than before.
2. State-owned enterprises: Lu Kang has developed 7 varieties and 8 batch numbers, ranking first among peers in terms of development volume; North China Pharmaceutical developed 6 varieties and 8 batches; Shandong Qilu has developed 5 varieties and 9 batches; Shandong Xinhua has developed 4 varieties and 7 batch numbers; Jiangsu Yangtze River develops 4 varieties and 8 batch numbers; Zhejiang Haizheng develops 4 varieties and 7 batch numbers; Shanghai Xinya has developed 3 varieties and 4 batch numbers. Geographically, pharmaceutical companies in Shandong have developed 16 varieties and 24 batch numbers, forming the "Lujun".
3. Joint venture: Shanghai Johnson & Johnson has developed 7 varieties and 7 batch numbers; Zhuhai Federally developed 5 varieties with batch number 10, which is in the forefront. In addition, Chongqing GlaxoSmithKline, Suzhou Zhonghua, Hangzhou Zhongmei Huadong, Guangzhou Nanxin, Suzhou Puqiang, Tianjin Wutian, Xi 'an Janssen, Tianjin Zhongmei SmithKline, Bayer * * * and other 18 enterprises have developed 22 varieties and 35 batch numbers. This shows that enterprises have attached great importance to the development of new drugs under the background of the gradual opening up of the pharmaceutical field in China, and the development of new drugs has become the killer of pharmaceutical enterprises.
Second, 2020 pharmaceutical enterprises 100 list interpretation
The list of pharmaceutical enterprises in 2020 shows that the main business income of 100 enterprises before the list is 90 12 1 billion yuan, which is 3. 1% lower than the previous year's 929.64 billion yuan. This is the first time that China's pharmaceutical industry has shown a downward trend in recent 10 years. In addition, the average R&D expenditure of the top 100 enterprises is 633 million yuan, and the average R&D intensity is 6.8%, both of which are the highest in history. In terms of sub-fields, in the top list of pharmaceutical industry 100, there are 56 chemical preparation enterprises, 2 Chinese patent medicine enterprises1family, 7 biological products enterprises and 4 sanitary materials and medical devices enterprises. In addition, in terms of regional distribution, there are 65 pharmaceutical industrial enterprises in the Yangtze River Delta, Beijing-Tianjin-Hebei, Greater Bay Area and Chengdu-Chongqing regions. On the whole, among the 1 and 16 new drugs approved for marketing in 2020, 7 are from the top 100 enterprises, which proves the important position of the top 100 enterprises in the industry.